HY-115524-1mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-115524-10mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-115524-100mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-115524-25mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-115524-5mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-115524-50mg
|
MedChemexpress LLC
|
DBCO-NHS ester 2 [CAS 1384870-47-6]
|
|
Neuroscience-Neuromodulation
|
|
HY-15579B-10mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-15579B-100mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-15579B-5mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-15579B-50mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-79253-100mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
HY-79253-25mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
HY-79253-50mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
HY-P1449A-10mg
|
MedChemexpress LLC
|
Boc-Gly-Gly-Phe-Gly-OH (TFA) [CAS 2450273-39-7]
|
|
Neuroscience-Neuromodulation
|
|
HY-P1449A-5mg
|
MedChemexpress LLC
|
Boc-Gly-Gly-Phe-Gly-OH (TFA) [CAS 2450273-39-7]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99017-1mg
|
MedChemexpress LLC
|
Eptinezumab [CAS 1644539-04-7]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99017-10mg
|
MedChemexpress LLC
|
Eptinezumab [CAS 1644539-04-7]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99017-5mg
|
MedChemexpress LLC
|
Eptinezumab [CAS 1644539-04-7]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99019-1mg
|
MedChemexpress LLC
|
Fremanezumab [CAS 1655501-53-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99019-10mg
|
MedChemexpress LLC
|
Fremanezumab [CAS 1655501-53-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99019-5mg
|
MedChemexpress LLC
|
Fremanezumab [CAS 1655501-53-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99021-1mg
|
MedChemexpress LLC
|
Galcanezumab [CAS 1578199-75-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99021-10mg
|
MedChemexpress LLC
|
Galcanezumab [CAS 1578199-75-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99021-5mg
|
MedChemexpress LLC
|
Galcanezumab [CAS 1578199-75-3]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99105-1mg
|
MedChemexpress LLC
|
Anselamimab [CAS 2414866-63-8]
|
|
Neuroscience-Neuromodulation
|
|